OTCMKTS:CLPBY - Coloplast A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $985.00
  • Forecasted Upside: 8,233.40 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$11.82
▲ +0.09 (0.77%)

This chart shows the closing price for CLPBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coloplast A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLPBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLPBY

Analyst Price Target is $985.00
▲ +8,233.40% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Coloplast A/S in the last 3 months. The average price target is $985.00, with a high forecast of $990.00 and a low forecast of $980.00. The average price target represents a 8,233.40% upside from the last price of $11.82.

This chart shows the closing price for CLPBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Coloplast A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/10/2022JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral1,014.00 ➝ 980.00
1/26/2022DNB MarketsUpgradeSell ➝ Hold
1/19/2022JPMorgan Chase & Co.Lower Price Target1,038.00 ➝ 1,033.00
1/10/2022BarclaysBoost Price Target975.00 ➝ 990.00
11/11/2021CheuvreuxUpgradeHold ➝ Buy
11/2/2021JPMorgan Chase & Co.Reiterated RatingNeutral
11/2/2021Nordea Equity ResearchDowngradeHold ➝ Sell
10/13/2021BarclaysReiterated RatingEqual Weight
9/10/2021BarclaysReiterated RatingEqual Weight
8/19/2021Credit Suisse GroupReiterated RatingOutperform
8/19/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/11/2021Kepler Capital MarketsDowngradeBuy ➝ Hold1,144.00
7/15/2021BarclaysReiterated RatingEqual Weight
5/18/2021Berenberg BankReiterated RatingHold
5/7/2021JPMorgan Chase & Co.Reiterated RatingNeutral
3/9/2021CommerzbankUpgradeReduce ➝ Buy
3/8/2021BarclaysUpgradeUnderweight ➝ Equal Weight
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutral
2/3/2021Morgan StanleyReiterated RatingEqual Weight
1/20/2021Berenberg BankUpgradeSell ➝ Hold
1/13/2021BarclaysReiterated RatingUnderweight
12/9/2020Morgan StanleyReiterated RatingEqual Weight
11/6/2020Morgan StanleyReiterated RatingEqual Weight
11/4/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/16/2020Berenberg BankReiterated RatingSell
9/23/2020BarclaysDowngradeEqual Weight ➝ Underweight
9/23/2020Jefferies Financial GroupUpgradeHold ➝ Buy
8/19/2020JPMorgan Chase & Co.Reiterated RatingNeutral
8/19/2020Morgan StanleyReiterated RatingEqual Weight
8/11/2020Nordea Equity ResearchDowngradeHold ➝ Sell
4/27/2020BarclaysReiterated RatingEqual Weight
4/20/2020JPMorgan Chase & Co.Reiterated RatingNeutral
3/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
7/19/2019BarclaysDowngradeOverweight ➝ Equal Weight
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/14/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/13/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/13/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Coloplast A/S logo
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Read More

Today's Range

Now: $11.82
Low: $11.81
High: $12.09

50 Day Range

MA: $11.34
Low: $10.42
High: $11.90

52 Week Range

Now: $11.82
Low: $10.18
High: $18.23

Volume

41,344 shs

Average Volume

111,982 shs

Market Capitalization

$25.53 billion

P/E Ratio

42.21

Dividend Yield

1.47%

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Coloplast A/S?

The following Wall Street sell-side analysts have issued stock ratings on Coloplast A/S in the last twelve months: Barclays PLC, Cheuvreux, Credit Suisse Group AG, DNB Markets, JPMorgan Chase & Co., Kepler Capital Markets, and Nordea Equity Research.
View the latest analyst ratings for CLPBY.

What is the current price target for Coloplast A/S?

2 Wall Street analysts have set twelve-month price targets for Coloplast A/S in the last year. Their average twelve-month price target is $985.00, suggesting a possible upside of 8,233.4%. Barclays PLC has the highest price target set, predicting CLPBY will reach $990.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $980.00 for Coloplast A/S in the next year.
View the latest price targets for CLPBY.

What is the current consensus analyst rating for Coloplast A/S?

Coloplast A/S currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLPBY, but not buy more shares or sell existing shares.
View the latest ratings for CLPBY.

What other companies compete with Coloplast A/S?

How do I contact Coloplast A/S's investor relations team?

Coloplast A/S's physical mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The company's listed phone number is (454) 911-1111 and its investor relations email address is [email protected] The official website for Coloplast A/S is www.coloplast.com. Learn More about contacing Coloplast A/S investor relations.